It is currently trading at $1.23 which is marginally lower than $1.34, the 50 day moving average and which is significantly lower than the 200 day moving average of $1.41. The 50 day moving average was down $-0.11 or -8.21% whereas the 200 day moving average was down $-0.18 or -12.92%. Trading was heavy with 250K shares changing hands by the end of trading on Tuesday. Overall, volume was up 13.53% over the stocks normal daily volume.
Traders are feeling more bearish on shares of the company recently considering the motion in short interest. The company realized a rise in short interest between September 29, 2017 and October 13, 2017 of 2.96%. Short interest grew 18,290 over that period. The short-interest ratio increased to 5.0 and the percentage of shorted shares was 0.01% on October 13.
Here are a few substantial investment firms who have updated their positions. Jw Asset Management, LLC grew its investment by buying 130,000 shares an increase of 15.6%. Jw Asset Management, LLC now controls 966,000 shares worth $1,343,000. The total value of its holdings increased 14.8%. Venbio Select Advisor LLC added to its stake by buying 100,000 shares an increase of 1.7% as of 06/30/2017. Venbio Select Advisor LLC controls 5,891,581 shares with a value of $8,189,000. The value of the position overall is up by 1.0%.
Armistice Capital, LLC augmented its position by buying 1,464,000 shares an increase of 33.0% in the quarter. Armistice Capital, LLC now holds 5,900,000 shares valued at $8,201,000. The total value of its holdings increased 32.1%. As of quarter end Livingston Group Asset Management Co (operating As Southport Capital Management) had sold a total of 100 shares trimming its stake by 0.3%. The value of the total investment in Alimera Sciences, Inc. went from $47,000 to $45,000 a change of $2,000 since the last quarter.
In the last earnings report the EPS was $-0.39 and is projected to be $-0.20 for the current year with 69,050,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-0.02 and the next full year EPS is projected to be $-0.09.
Alimera Sciences, Inc. (Alimera), launched on June 4, 2003, is a pharmaceutical company. The Company is involved in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Business’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies..